First-line pemigatinib in a myeloid/lymphoid neoplasm with FGFR1 rearrangement: shifting the current treatment paradigm.
A 69-year-old female with newly diagnosed MLNFGFR1 in blast phase, presenting with concurrent myeloproliferative neoplasm and T-lymphoblastic lymphoma remains in complete remission at 17 months after pemigatinib initiation, with treatment-related toxicity being manageable through dose modifications and temporary interr...